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1. Introduction 
Chemotherapy and hormonal therapy play important role in the treatment of breast cancer, 
a leading cause of cancer death in women. Although there are a lot of effective medicines 
applied, a significant number of patients do not respond to these therapeutic agents. Drug 
resistance, in addition to side effects of chemotherapy and hormonal therapy, necessitates 
the search for new specific tumor targeting compounds. Breast cancer cell lines have been 
widely used not only to investigate breast cancer pathobiology, but also to screen and 
characterize new therapeutics. Especially MCF-7 and MDA-MB-231 breast cancer cell lines 
often serve as in vitro models in cancer research. In this chapter, some of new compounds 
which showed antiproliferative and cytotoxic effects against MCF-7 and/or MBA-MB-231 
breast cancer cell lines are presented.  
2. Minor groove binders (MGB) 
The minor groove of double helical B-DNA is becoming a site of a great interest for 
developing new drugs since it is the site of non-covalent high sequence specific interactions 
for a large number of small molecules. Minor groove binders are one of the most widely 
studied class of agents characterized by a high level of sequence specificity and possessing 
varied biological activities. Most of them exhibit antiviral, antibacterial and antiprotozoal 
properties. Furthermore, some of these have shown antitumor activity.  
The focus of this chapter will be on anti-cancer compounds, active against MCF-7 and/or 
MBA-MB-231 breast cancer cell lines, which are derived from the non-covalent minor 
groove binders such as netropsin, distamycin A and related compounds, the Hoechst 
33258, DAPI, berenil or pentamidine (Fig.1). These compounds interact only physically 
with DNA and cause only reversible inhibition of DNA-dependent functions. They 
possess an inherent curvature that matches approximately the helical curve of the minor 
groove of B-DNA.  
The DNA binding process in the minor groove can be described by two steps (Bailly & 
Chaires, 1998). In the first, electrostatic and hydrophobic interactions transfer the ligand 
from solution into the DNA minor groove. In the case of positively charged compounds, 
such as distamycin, this results in DNA counter-ion exchange. In the second step, various 
specific interactions are established between the bound ligand and the functional groups of 
the base pairs of the DNA. The interactions usually include a combination of hydrogen 
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bonds, hydrophobic and van deer Waals contacts, and electrostatic interactions (Gallmeier & 
König, 2003). 
 
N
CH3
HN
O
H
HN
N
O
CH3
HN
O
N
CH3
HN
HN
NH2
O
HN
HN
N
O
CH3
HN
O
N
CH3
HN
HN
NH2
O
NH2
HN
netropsin distamycin
N
HN
N
HN
N
HO
N
H3C
N
N
NH
HN
NH2
HN
NH2
HN
NH2
HN
HN
NH2
O
HN
NH2
HN
NH2
O
pentamidineHoechst 33258 berenil DAPI  
Fig. 1. Structures of minor groove binders. 
Although DNA minor groove binding drugs have been extensively reviewed in the last 
years, defining the chemical and biological aspects of the newly synthesized compounds, 
only few of them have shown antitumor activity and reached clinical trials.  
2.1 Carbocyclic analogues of distamycin and netropsin 
Distamycin and netropsin have been shown to be highly DNA sequence-specific and bind 
preferentially to AT-rich regions of DNA. These oligoamides are highly polar compounds 
that nevertheless show significant cytotoxic properties.  
DNA-binding model of netropsin and distamycin become the inspiration to searches of new 
compounds with similar interaction to DNA. The class of synthetic heteroaromatic 
oligopeptides, projected after the models the netropsin and distamycin, received the name 
lexitropsins (Kopka et al., 1985). Lexitropsins connected with molecules of different known 
drug, e.g. alkylating agents, are called combilexins (Sondhi et al., 1997). Until now 
thousands of MGB analogues have been synthesized and some reviews about recent results 
about analogues of netropsin, distamycin and of some lexitropsins and combilexins or 
related hybrid molecules with sequence reading, intercalating or alkylating activity were 
described and evaluated for prospective applications (Bailly & Chaires, 1998; Baraldi et al., 
2004; Nelson et al. 2007; Pindur et al, 2005; Reddy et al. 2001). Here the carbocyclic 
lexitropsins are presented. 
The derivatives containing benzene in place of N-methylpyrrole rings, with a minor 
modification of cationic heads, bind to AT sequences less strongly than the extensively 
studied MGB, however these compounds show sequence selectivity. It is worth noting that 
carbocyclic analogues of netropsin and distamycin are readily available, can be modified 
easily, and are stable under most experimental conditions.  
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Fig. 2. Structures of carbocyclic netropsin and distamycin analogues. 
The showed compounds 5A and 5B possess a dimethylamino group in place of the 
amidinium moiety normally present in netropsin. The synthesis of such C-terminus-
modified analogues provides a number of advantages. First, the compounds containing a 
modified terminus are chemically stable, and thus the synthetic methodology is readily 
adaptable to preparation of further analogues. Second, they are not hygroscopic and are 
easy to handle. Third, the dimethylamino group is uncharged, and thus column 
chromatography or recrystallization can readily purify products and intermediates. Finally, 
with a pKa about 9.3, this moiety would be protonated at physiological pH of 7.4 to provide 
favorable electrostatic attraction to the negative electrostatic charge of DNA. The 
compounds 7A and 7B have the requisite charged end groups and number of potential 
hydrogen-bonding loci equal to that of distamycin. To obtain information on the DNA 
binding modes of these types of compounds, additional derivatives, 5B and 7B, substituted 
in ortho position to amide moieties of each phenyl ring with a methoxy group were 
synthesized and designed to provide improved distinction between minor-groove and 
intercalation binding modes. The methoxy group protrudes from the plane of the aryl ring 
and would unfavourable clash with the aromatic rings of the base pairs in the intercalation 
cavity of DNA.  
Compounds of this type have the potential for development as carriers for the groove-
specific delivery of functionalized groups to DNA and as template inhibitors of 
transcription. Described compounds were tested for their antitumour activity in the 
standard cell line of the mammalian tumour MCF-7. The compounds concentration, which 
inhibits 50% of colony formation, is in the range 24.43 – 105.35 μM, whereas IC50 for 
netropsin studied in the same cell line, is 5.40 μM and for distamycin is 56.95 μM.  
During the past years, studies have indicated that antitumour activity of DNA-binding 
drugs is, at least in part, the result of the inhibition of enzymes that regulate DNA topology: 
the topoisomerases. Compounds 7A and 7B inhibited topoisomerases activity contrary to 
5A and 5B. This fact indicates that topoisomerase inhibition is selective and sensitive to the 
number of repeating benzene carboxamide units – a minimum of three benzene 
carboxamide units are necessary for the inhibition of topoisomerases.  
On the basis of molecular modelling it seems that the structure of benzene oligopeptides 
might be a useful starting framework for synthesis of selective DNA minor groove binding 
molecules. Molecular modelling of their interaction with d(CGCGAATTCGCG)2 showed 
that their structure are effectively isohelical with DNA minor groove however with 
decreased affinity for the minor groove of AT-rich regions in comparison to netropsin and 
distamycin. From the energetic analysis it appeared that van der Waals and electrostatic 
interactions are more important than specific hydrogen bonds in stabilizing the ligand-
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duplex complexes. Compounds 5A and 5B are effectively isohelical with the DNA minor 
groove. The superior DNA-binding afforded by 5A and 5B in comparison to 7A and 7B 
results from their more effective penetration into minor groove and smaller perturbation of 
molecular structure upon complex formation (Bielawski et al., 2000). 
In continuation of rational drug design program aiming to develop distamycin analogues, 
potential minor-groove binders, and inhibitors of topoisomerases, compounds 1C - 8C and 
1D - 6D (Fig. 3) were synthesized and examined. This compound skeleton was combined 
the structural features of distamycin and furamidine. 
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Fig. 3. Structures of distamycin analogues. 
Distamycin analogues 1C - 8C were tested for in vitro cytotoxicity towards human breast 
cancer cells MCF-7 and MDA-MB-231. All of these compounds showed antiproliferative and 
cytotoxic effects against both cell lines in the range 3.47 – 12.53 μM for MDA-MB-231 and 
4.35 – 12.66 μM for MCF-7. All of compounds demonstrated activity against DNA 
topoisomerases I and II at the concentration 50 μM. Ethidium bromide assay showed that 
these compounds bind to plasmid pBR322 but weaker than distamycin. The most interesting 
seems compound 1C with a time-dependent reduction in proliferation observed in both cell 
lines at concentrations: 6.38 μM for MCF-7 and 8.79 μM for MDA-MB-231. Compound 5C 
with IC50 respectively 10.99 μM for MCF-7 and 3.47 μM for MDA-MB-231 cells is also 
interesting. All of investigated compounds are more potent than chlorambucil, which MCF-
7 IC50 averages 24,6 µM. The most active analogues due to possession a free amino group 
can serve as potential carriers of strong acting elements, e.g. alkylating groups. 
All of new oligopeptides 1D - 6D exhibit tumour cell cytotoxicity towards the standard cell 
line of the mammalian tumour MCF-7 and IC50 of examined compounds is in the range 
183.53 – 232.50 μM. It is similar value as other minor groove binder DAPI (IC50=176 μM) but 
weaker than distamycin with IC50=56.95 μM or Hoechst 33258 (IC50=55 μM) and presented 
earlier analogue of distamycin 7A (40.73 μM). 
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Both presented groups of compounds demonstrated activity against DNA topoisomerase I 
and II. Ethidium bromide assay showed that these compounds bind to plasmid pBR322 but 
weaker than distamycin.  
2.2 Other carbocyclic potential MGB 
As a part of ongoing rational drug design programme aiming at development of carbocyclic 
minor groove binders six other compounds were synthesized and evaluated (Fig.4).  
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Fig. 4. Structures of carbocyclic potential MGB. 
All of the tested compounds showed concentration-dependent activity. Against MDA-MB-
231 cells, compounds are more cytotoxic than pentamidine with IC50 = 17.74 μM and 
netropsin with IC50 = 228.80 μM. The compound concentration that inhibited 50% of colony 
formation is in the range 8.10 to 17.52 μM. IC50 against MCF-7 cell line were in the range 
209.8 to 406.62 μM, while IC50 of pentamidine was 14.31 μM and netropsin 5.40 μM. From 
these data we can see that the compounds 1-6 are nearly twenty times more active against 
MDA-MB-231 than against MCF-7 cells.  
Data from relaxation assays of topoisomerase I and II demonstrated that compounds 1-6 
have topoisomerase I inhibitory activity in the range from 10 to 40 μM and topoisomerase II 
inhibitory activity in the range from 30 to 100 μM.  
The influence of compounds 1-6 on the amidolytic activity of urokinase, thrombin, plasmin 
and trypsin was also investigated. Compounds 1, 2 and 3 are ineffective as amidolytic 
activity inhibitors. None of investigated compounds inhibited activity of thrombin. 
Compounds 4-6 are inhibitors of plasmin meanwhile amidolytic activity of urokinase inhibit 
5 and 6. Trypsin activity is inhibited only by compound 6. 
The investigation compounds showed interesting spectrum of their activity. We can see that 
they bind to minor groove B-DNA and inhibit topo I and topo II activity. Some of them are 
also inhibitors of plasmin and urokinase. The differences in antiproliferative and cytotoxic 
effect against MCF-7 and MBA-MD-231 breast cancer cell lines demonstrate that mechanism 
of action of our compounds is not dependent only from DNA-binding mode but can be 
partially connected with the fact that in the case of MDA-MB-231 cells higher uPA/uPAR 
(urokinase plasminogen activator system) expression and high plasminogen-binding was 
observed than in MCF-7 cell line (Dass et al., 2008).  
2.3 Bisamidine derivatives  
The aromatic bisamidines, such as DAPI, berenil or pentamidine (Fig.1.), exhibit a wide 
spectrum of antimicrobial, antiviral, and antitumour properties (Baraldi et al., 2004). A 
number of natural and synthetic bisamidines are known to bind to B-DNA (Bailly & 
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Chaires, 1998). However, the precise genomic targets and modes of action these ligands are 
not known. Most studies have focused on the abilities of bisamidines to inhibit the binding 
of regulatory proteins to oligonucleotide length recognition sequences that are rich in A and 
T base pairs. The lack of quantitative correlation between DNA binding and antimicrobial 
and antitumour activity for these molecules in all of the organisms studied can be attributed 
to the idea that DNA binding is only the first step in a multistep process.  
To investigate DNA binding properties of bisamidines derivatives, novel extended 
diphenylfuran analogues KB1-KB4 (Fig.5) possessing different dicationic terminal side 
chains were synthesized (Bielawski et al., 2001b). In the topoisomerase II assay, the 
relaxation of DNA was inhibited with all four drugs and the extent of inhibition was directly 
proportional to the drug concentration. Compounds KB2-KB4 did not inhibit the 
topoisomerase I mediated relaxation of supercoiled DNA, compound KB1 showed 
inhibiting activity at 80 μM. 
 
O
NH
HN
H
N
O
O
HN
NH
HN
O
O
NH
HN
NH
O
O
HN
NH
HN
O
O
NH
HN
H
N
O
O
HN
NH
HN
O
KB2
KB3
KB4
O
NH2
HN
NH
O
O
H2N
NH
HN
O
KB1
 
Fig. 5. Structures of novel bisamidines. 
The ultrafiltration assay showed that examined compounds have significant affinity for 
DNA. The DNA-binding data using homopolymers poly(dA-dT) . poly(dA-dT) and 
poly(dG-dC) . poly(dG-dC) indicated that these compounds show moderate specificity for 
AT base pairs. The cytotoxicity effects of KB1-KB4 were studied in cultured breast cancer 
MCF-7 cells and found to be 63 μM, 85 μM, 77 μM and 97 μM, respectively. The novel 
bisamidines showed comparable antitumour activity to Hoechst 33258, but were 
substantially more cytotoxic compared to DAPI. These data showed that in broad terms the 
cytotoxic potency of bisamidines KB1-KB4 in cultured breast cancers MCF-7 cells decreases 
with the size of the alkyl group substituent (cyclopropyl > isopropyl > cyclopentyl), in 
accord with their increases in DNA affinity (Bielawski et al., 2001a). This suggests that 
DNA-binding may be implicated in the cytotoxicity of these bisamidines, possibly by 
inhibiting interactions between cellular proteins and their DNA targets. 
3. Synthetic minor groove binders as carriers for alkylating moieties 
DNA alkylating agents are a major class of anticancer drugs for the treatment of various 
cancers including breast cancer. The first nitrogen mustard used in therapy was 
mechlorethamine, and the related compounds chlorambucil, melphalan, and 
cyclophosphamide remain in use today. A drawback common to all DNA alkylating agents 
is their high chemical reactivity. This can result in loss of drug by reaction with other 
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cellular nucleophiles, particularly proteins, and low-molecular weight thiols. This makes 
them vulnerable to cellular resistance mechanisms such as increased levels of glutathione. 
Other limitations, discussed particularly for mustards, are a lack of intrinsic DNA binding 
affinity of the core N,N-bis(2-chloroethyl)amine pharmacophore, and a requirement for 
bifunctional cross-linking of DNA to be fully cytotoxic. These characteristic lower their 
potency and the observed high ratio of genotoxic monoadducts to cross-links (up to 20:1) 
contributes to their known carcinogenicity. There is also evidence that the major guanine N7 
adduct formed by mustards and other alkylators is readily repaired, which may also result 
in lower cytotoxicity (Osborne et al., 1995). For these reasons there has been much interest in 
the concept of specially targeting alkylating agents to DNA by attaching them to DNA affine 
carrier molecules, as this could in principle address these limitations. Increasing the 
concentration of drug in the vicinity of DNA would mean less chance of losing active drug 
by reaction with other cell components. Additionally, the use of DNA-affine carriers with 
their own defined binding geometry makes it possible to alter both the region and sequence 
specificity of alkylation compared with that of the alkylators  
3.1 Distamycin related alkylating agents 
Work on the targeting of nitrogen mustard alkylating agents to DNA by the use of DNA 
minor groove-binding ligands has shown that this strategy can greatly enhance both the in 
vitro cytotoxicity and the in vivo antitumour activity of the mustard moiety, when compared 
with untargeted mustards of similar reactivity. The main representative of this class that 
was clinically tested is tallimustine (Fig. 6), a benzoic acid nitrogen mustard derivative of 
distamycin (Cozzi, 2003).  
 
N
Cl
Cl
H
N
O
N
O
H
N
N
CH3
O
HN
N
HN
O
H2N
NH
CH3
CH3
N
CH3
HN
O
4
H
N
HN
NH2
HCl.
NH
Br
O
TALLIMUSTINE
BROSTALLICIN  
Fig. 6. Structures of tallimustine and brostallicin. 
Tallimustine (TAM) showed cytotoxicity against L1210 murine leukemia more than two 
orders of magnitude higher then distamycin and more than one order of magnitude higher 
then classical nitrogen mustard melphalan. This compound is a very sequence and 
regiospecific alkylator, reacting only by monoalkylation at the N3 position of the 3’-adenine 
in the sequence 5’-TTTTGA-3’. 
Whereas the cytotoxicity of TAM is related to the ability to form interstrand cross-links in 
DNA with consequent inhibition of DNA replication and transcription, the mechanism of 
antitumour action of tallimustine, although it is not yet fully elucidated may be due to its 
ability to inhibit the binding of some transcription factors to their consensus sequences in 
DNA. The cell cycle phase perturbations caused by tallimustine and melphalan were 
different and can be related to the different DNA damage done by these two drug. 
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Tallimustine showed excellent antitumor activity in preclinical tests, but also a severe 
myelotoxicity (Cozzi, 2003). 
A second generation DNA minor groove binder, structurally related to distamycin is 
brostallicin (PNU-166196), alpha-bromo-acrylamido tetra-pyrrole derivative ending with a 
guanidino moiety (Fig.6). This compound showed broad antitumour activity in preclinical 
models and dramatically reduced in vitro myelotoxicity in human hematopoietic progenitor 
cells compared with that of TAM and other MGB. Brostallicin showed a 3-fold higher 
activity in melphalan-resistant L1210 murine leukemia cells than in the parental line (IC50-
0.46 and 1.45 ng/ml, respectively) under conditions in which the cytotoxicity of 
conventional antitumor agents was either unaffected or reduced. This melphalan-resistant 
cell line has increased levels of glutathione (GSH) in comparison with the parental cells. 
Conversely, GSH depletion by buthionine sulfoximine in a human ovarian carcinoma cell 
line (A2780) significantly decreased both the cytotoxic and the proapoptotic effects of 
brostallicin. A 2–3-fold increase in GST-levels resulted in a 2–3-fold increase in cytotoxic 
activity of brostallicin. Similar results were obtained for GST-transfected human breast 
carcinoma cells (MCF-7). 
In an in vivo experiment, A2780 clones were implanted into nude mice. The antitumor 
activity of brostallicin was higher in the GST-overexpressing tumors without increased 
toxicity. Regarding the mechanism of action, brostallicin interacts reversibly with the DNA 
minor groove TA-rich sequences but appears unreactive in classical in vitro DNA alkylation 
assays. Evidence of both covalent interaction of brostallicin with plasmidic DNA in the 
presence of GSH and of enhanced cytotoxicity in cancer cells characterized by high levels of 
GSH was obtained (Geroni et al., 2002). Brostallicin was selected for clinical development 
and is presently in clinical trials in Europe and the United States (Fedier et al. 2003). The 
phase II of studies of brostallicin in combination with cisplatin for metastatic breast cancer is 
currently in the stage of testing. 
3.2 Carbocyclic lexitropsins with chlorambucil moiety 
The carbocyclic lexitropsins investigated so far were not such active to be used as agent in 
breast cancer therapy but the application of them as potential carriers of strong acting 
elements was also examined. For example, derivatives with N-terminal chlorambucil group 
have been synthesized (Fig.7.).  
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Fig. 7. Structures of carbocyclic lexitropsins with chlorambucil moiety. 
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After the molecular mechanics refinement calculations, energetically favoured complexes of 
compounds DB1 and DB3 with d(CGCGAATTCGCG)2 were obtained (Fig.8.)  
 
 
Fig. 8. Views of the low-energy complexes formed between the d(CGCGAATTCGCG)2 and 
the carbocyclic analogues of distamycin after MD refinement. Left - DB1; right - DB3. 
Ligands molecules are shown in green. 
Compounds DB1 and DB3 form centrosymetric 4 bp complexes with the ligands displaced 
towards the 5’ end of the 5’-AATT binding site. This displacement facilitates increased 
Waals contacts with the walls of the minor groove. In addition to the decreasing affinity for 
the 5’-AATT-3’ match site, there are weaker contacts with the O2 atom of C21 indicating that 
the binding-site size requirement for DB1 and DB3 extends over slightly more than the four 
central AT base pairs. The energy wells for these ligands within this AT tract are narrow and 
the data indicate that specific interactions with flanking sequences strongly inhibit ligand 
translation along the minor groove. The benzene rings DB1 and DB3 are positioned roughly 
in the plane of the bases and the amide groups are located between base pairs. No regular 
pattern of bifurcated hydrogen bonds then exists. From the analysis of these complexes it 
appears that van deer Waals and electrostatic interactions are more important in stabilizing 
the complexes than specific hydrogen bonds formation. This is consistent with the observed 
reduced affinity to AT pairs and increased affinity towards GC sequences of the carbocyclic 
lexitropsins with chlorambucil moieties in comparison with distamycin and netropsin. The 
protonated terminal dimethylamine nitrogen of the (dimethylamino)propyl tail is adjacent 
to a negatively charged phosphodiester linkage. The hydrophobic methoxy groups of DB3 
are situated outside the minor groove; therefore, the binding energies for DB1 and DB3 are 
almost the same. Compounds DB1 and DB3 produce an increase in groove width of ca. 1.5 
Å compared with the netropsin-DNA complex (Kopka et al., 1985). Because of flexibility of 
the aliphatic tether of chlorambucil moiety, there is probably a limited distribution of 
alkylation sites derived from an individual binding complex rather than a unique alkylation 
site for each individual bound compound. An accurate definition by molecular modelling of 
the optimal binding site for the compounds studied alone has been hampered by the fact 
that the DNA fragment used in the model contains a limited number of binding sites. 
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The DB1-DB4 compounds concentration, which inhibits 50% of breast cancer MCF-7colony 
formation, is in the range 85 - 104 μM. In the case of DB5-DB7 compounds, this 
cconcentration is in the range 66 to 124 µM. All of them induced cancer cell death by 
apoptosis and necrosis.  
3.3 Amidine analogues of chlorambucil 
Also a number of novel cyclic amidine analogs of chlorambucil (Fig.9) were synthesized and 
examined for cytotoxicity in breast cancer cell cultures.  
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Fig. 9. Structures of amidine analogues of chlorambucil AB7-AB9. 
In terms of reduction in cell viability, the compounds rank in both MCF-7 and MDA-MB-231 
cells in the order AB9 > AB7 > AB8 > chlorambucil. The values of IC50 were relatively 
higher for AB 9 and AB 7 which possess a cationic 4,5-dihydro-1Himidazol and amidine 
function, respectively. Among the derivatives, compound AB 8 in both MDA-MB-231 and 
MCF-7 proved to be only slightly more potent than chlorambucil, with IC50 values of 70 and 
76 μM, respectively, compared to 92 and 97 μM for chlorambucil. In contrast, compound 
AB9, which contains the 4,5-dihydro-1Himidazol moiety is clearly much more active and 
showed a high level of cytotoxic potency, IC50 22 and 18 μM in MCF-7 and MDA-MB-231, 
respectively. Compound AB9, the most active of the series, is approximately five times more 
potent than chlorambucil.  
The degree to which these compounds inhibited cell growth breast cancer cells was directly 
correlated to DNA-binding affinity. 
The ability of compounds AB7–9 to inhibit topoisomerases I and II activity was quantified 
by measuring the action on supercoiled pBR322 DNA substrate as a function of increasing 
concentration of the ligands by the use of agarose gel electrophoresis. Chlorambucil as a 
control was, as expected, ineffective in this assay. The investigation indicate that cyclic 
amidine analogs of chlorambucil are a potent catalytic inhibitor of topoisomerase II but not 
topoisomerase I. Compound AB9 was the most potent topoisomerase II inhibitors, with 50% 
inhibitory concentration (IC50) 5 μM. (Bielawska et al., 2004). 
Compound AB7 and chlorambucil were compared for their effects on collagen and DNA 
synthesis in breast cancer MDA-MB-231 cells. IC50 values for chlorambucil and its amidine 
analogue for collagen synthesis were found to be about 44 and 19 μM, respectively. 
Increased ability of AB7 to suppress the protein synthesis, compared to chlorambucil, was 
found to be related to an inhibition of prolidase activity and expression. The phenomena 
were probably a result of disruption of β1-integrin and the insulin-like growth factor-I (IGF-
I) receptor mediated signaling caused by this compound. Expression of β1-integrin receptor, 
as well as focal adhesion kinase pp125FAK (FAK), growth-factor receptor-bound protein 2 
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(GRB2), son of sevenless protein 1 (Sos1) and phosphorylated mitogen activated protein 
kinases (MAPK), extracellular-signal-regulated kinase 1 (ERK1) and kinase 2 (ERK2) but not 
Src and Shc proteins was significantly decreased in cells incubated for 24 h with 10 μM AB7, 
compared to controls. Chlorambucil in the same conditions did not evoke any changes in 
expression of all these signaling proteins, as shown by Western immunoblot analysis. In 
addition, AB7 revealed a higher antiproliferative activity than chlorambucil, accompanied 
by a stronger down-regulation of IGF-I receptor expression. The results were confirmed by 
[3H]thymidine incorporation assay. Incubation of the cells with 10 μM AB7 for 12 and 24 h 
contributed to a decrease in DNA synthesis by about 33 and 46% of the control values, 
respectively, while in case of chlorambucil by about 23 and 29%, respectively. These data 
suggest that the amidine analogue of chlorambucil (AB7) disturbs MDA-MB 231 cell 
metabolism more potently than does the parent drug, chlorambucil. 
The mechanism of this phenomenon may be due to its stronger suppression of β1-integrin 
and IGF-I receptor signaling. (Sienkiewicz et al., 2005). 
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Fig. 10. Structures of amidine analogues of chlorambucil KB17-KB22. 
As continuation of chlorambucil analogues of amidines investigations, novel nitrogen 
mustard agents KB17–KB22 (Fig.10) involving 4-(N,N-bis(2-chloroethyl)-
aminophenyl)propylamine linked to a 5-(4-N-alkylamidinophenyl)-2-furancarboxylic acid 
moiety by the formation of an amide bond have been synthesized, characterized, and 
evaluated for their in vitro cytotoxic activity against MDA-MB-231 and MCF-7 human breast 
cancer cells. Evaluation of the cytotoxicity of KB17–KB22 employing a MTT assay and 
inhibition of [3H]thymidine incorporation into DNA demonstrated that these compounds 
exhibit remarkable cytotoxic effects in comparison with 4-[bis(2-
chloroethyl)amino]benzenebutanoic acid. Compounds KB17 and KB19, which possess a 
cationic amidine and 4,5-dihydro-1H-imidazol function moiety are approximately ten times 
more potent than 4-[bis(2-chloroethyl)amino]benzenebutanoic acid. The new compounds 
were evaluated as DNA topoisomerase II inhibitors. The cytotoxicity of the compounds 
KB17–KB22 correlates with their DNA binding affinities and their relative potency as 
topoisomerase II inhibitors (Bielawski et al., 2009). 
3.4 Amidine analogues of melphalan  
The amidine analogues of melphalan KB6-KB10 (Fig.11) differing by the nature of terminal 
basic side were synthesized and examined (Bielawska et al., 2007). Evaluation of the 
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cytotoxicity of these compounds was employing a MTT assay in both MDFA-MB-231 and 
MCF-7 human breast cancer cells. Although growth inhibition was concentration-dependent 
in either cell line, it was more pronounced at shorter times, in MCF-7 than MDA-MB-231. In 
terms of reduction in cell viability, the compounds rank in both MCF-7 than MDA-MB-231 
cells in the order KB7 > KB6 > KB8 > KB9 > KB10 > melphalan. 
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Fig. 11. Structures of amidine analogues of melphalan. 
The values of IC50 were relatively higher for KB7 which possess a cationic N-
cyclopropylamidine function. Among the derivatives, compound KB10 in both MDA-MB-
231 and MCF-7 proved to be only slight more potent than melphalan, with IC50 values of 117 
and 100 μM, respectively, and compared to 130 and 125 μM for melphalan. In contrast, 
compound KB7 is clearly much more active and showed a high level of cytotoxic potency, 
IC50 55 and 77 μM in MCF-7 and MDA-MB-231, respectively. Compound KB7, the most 
active of the series, is approximately 2 times more potent than melphalan. 
An attempt has also been made correlate the observed biological activity with 
topoisomerases inhibitory properties and DNA-binding properties of selected compounds. 
The cytotoxicity of the amidine analogues of melphalan towards cultured human breast 
cancer cells correlate with topoisomerase II inhibitory properties but not with DNA-binding 
properties.  
A molecular mechanics and molecular dynamics approach was used to examine the 
structure of complex formed between the d(CGCGAATTCGCG)2 duplex and compound 
KB7. It is predicted that this compound should have a decreased affinity for the minor 
groove of AT-rich regions in comparison to netropsin and furamidine. From the energetic 
analysis it appears that van der Waals and electrostatic interactions are more important than 
specific hydrogen bonds in stabilizing the ligand duplex, similarly like described earlier 
chlorambucil derivatives of carbocyclic lexitropsins. 
These experimental studies suggest that amidine analogues of melphalan KB6-KB10 may 
have other consequences for the metabolism of breast cancer cells. There were found that 
compound KB7 is a more potent inhibitor of collagen biosynthesis than a parent drug, 
melphalan (Bielawski et al., 2006).  
Melphalan foe 24 h did not affect the expression of proteins involved in the signaling 
cascade activated by β-integrin receptor. In contrast, compound KB7 inhibited expression of 
Shc and MAP-kinases in both estrogen receptor-positive and estrogen receptor-negative 
breast cancer cells. Decreased expression of FAK-kinase was found only in MDA-MB-231 
cells. Another important benefit evoked by the compound KB7 seems to be inhibition of 
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phospho-ERK’s activation (Bielawski et al., 2006). Upregulation of those kinases was found 
in various breast cancers (Santen et al., 2002). Blocking these kinases was found to have 
proapoptotic and antiproliferative effects on MDA-MB-231, that indicates a new target in the 
treatment of breast malignancies (Fukazawa et al., 2002). Induction of apoptosis by KB7 in 
both MDA-MB-231 and MCF-7 breast cancer cells was stronger than by the parent drug and 
run by activating caspase-3 (Sosnowska et al., 2009). 
These results and other recent studies indicate that the amidine analogues of melphalan 
represent multifunctional inhibitors of breast cancer cells growth and metabolism. 
3.5 Alkylating analogues of Hoechst 33258  
A series of carbamate derivatives of Hoechst 33258 was prepared as potential anticancer 
agents (Fig. 12).  
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Fig. 12. Structures of alkylating analogues of Hoechst 33258. 
These new compounds (I—IV) were readily prepared in good yields by addition of 
chloroethyl, bromoethyl, chloropropyl or 4-(chloromethyl)phenyl isocyanates to Hoechst 
33258. Their cytotoxic activity was evaluated on human breast cancer MCF-7. Compounds I-
IV were more cytotoxic than Hoechst 33258. In particular derivative IV, the most active of 
the series, is up to 3 times more potent than Hoechst 33258. The DNA-binding ability of 
these compounds was evaluated by an ultrafiltration method using calf thymus DNA. These 
data show that in broad terms the cytotoxic potency of I-IV in cultured breast cancer MCF-7 
cells increases, in accord with their increases in DNA affinity, as shown by the binding 
constant values (Bielawski at al., 2002). 
4. Conclusion 
An understanding of the mechanism, by which minor groove binding agents interact with 
DNA has led to the design of agents that can reversibly bind with high selectivity to 
extended DNA target sequences. Until now thousands of MGB analogues have been 
synthesized – here has been presented only small part of all investigations.  
The described results in the field of distamycin and netropsin, as well as other minor groove 
binders, and modifications of their structures give the expectation of obtaining a compound 
with required activity; which will be able to be applied as medical agent in anticancer 
therapy. Targeting alkylating moieties to DNA by attachment of DNA minor groove 
binding carrier, such as distamycin, netropsin, or Hoechst 33258 reduces the loss of active 
drug, due to reaction with other cell components and makes it possible to direct the 
alkylation both sequence specifically and regiospecifically. These compounds are able to 
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compete with natural substrates, such as specific transcription factors, and alter gene 
expression.  
An overall conclusion from this review is the increasing molecular-level knowledge about 
how the simpler minor groove binding agents bind to DNA. This in turn has fed into the 
design of agents that can reversibly bind with high selectivity to longer sequences of 
virtually any composition, which likely occur very seldom in the genome. Such compounds 
are highly effective tools, which are being explored in more and more complex biological 
systems. 
Although the biomedical sciences have recently been in intensive progress, it is difficult to 
find selective targets for caner chemotherapy. Still many of drugs used today for treating 
cancer patients, also patients with breast cancer, are in fact practically nonselective and 
exhibit severe toxicity to normal tissues. Hence, each new synthesized compound gives the 
chance to obtain a better result than previously. 
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